Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 4 5Phase 3 3Phase 2/3 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Hyperuricemia 2Tumor Lysis Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Interventional × rasburicase × Clear all
NCT00199043 2023-03-17

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma

Goethe University

Phase 3 Completed
80 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00607152 2014-05-08

Rasburicase (Fasturtec) Registration Trial

Sanofi

Phase 3 Terminated
10 enrolled

Hyperuricemia

NCT00230178 2010-01-12

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Sanofi

Phase 3 Completed
280 enrolled 10 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasms, Tumor Lysis Syndrome, Hyperuricemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡